Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.48 |
| ▸ | GABRD | O14764 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRE | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17021602 | 1.00 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL900317 | 1.00 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8965243 | 0.87 | ACHE (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8965248 | 0.87 | ACHE (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL26624391 | 0.85 | ACHE (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30527786 | 0.85 | ACHE (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29177079 | 0.84 | ACHE (0.47) | ACHEBACE1HCAR2 | |
| SCHEMBL12641603 | 0.84 | GABRP (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL814572 | 0.82 | CHRM1 (0.36) | ACHEBACE1CHRM1AKR1A1CHRM3 | |
| SCHEMBL809574 | 0.82 | CHRM1 (0.36) | ACHEBACE1CHRM1AKR1A1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260013535-A1 | STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS | CARGILL, INCORPORATED (US) | 2026-01-15 | — | — | US | disclosed |
| US-12458049-B2 | Steviol glycoside solubility enhancers | CARGILL, INCORPORATED (US) | 2025-11-04 | — | — | US | disclosed |
| US-11717549-B2 | Steviol glycoside solubility enhancers | CARGILL, INCORPORATED (US) | 2023-08-08 | — | — | US | disclosed |
| US-20220323528-A1 | STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS | CARGILL, INCORPORATED (US) | 2022-10-13 | — | — | US | disclosed |
| CN-112745419-B | Process for producing olefin-unsaturated carboxylic acid copolymer and olefin-unsaturated carboxylic acid copolymer | 中国石油化工股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-112745424-B | Method for preparing olefin-unsaturated carboxylic acid copolymer | 中国石油化工股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-112745423-B | Preparation method of olefin-unsaturated carboxylic acid copolymer, olefin-unsaturated carboxylic acid copolymer and application thereof | 中国石油化工股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-112745430-B | Process for producing olefin-unsaturated carboxylic acid copolymer | 中国石油化工股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-111116806-B | Preparation method of olefin-unsaturated carboxylic acid copolymer | 中国石油化工股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| CN-111116802-B | Preparation method of olefin-unsaturated carboxylic acid copolymer | 中国石油化工股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| EP-2621923-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | Intervet International B.V. (NL) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041872-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
| EP-2064253-B1 | AMPHOLYTIC COPOLYMER BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS | BASF SE (DE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009103735-A1 | COMPOSITION CONTAINING AN AMPHOLYTIC COPOLYMER ON THE BASIS OF QUATERNISED MONOMERS CONTAINING NITROGEN AND AT LEAST ONE POLYMER THAT DIFFERS FROM SAID COPOLYMER, AND USE THEREOF | BASF SE (DE) | 2009-08-27 | — | — | WO | disclosed |
| EP-2064253-A1 | AMPHOLYTIC COPOLYMER BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS | BASF SE (DE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008031892-A1 | AMPHOLYTIC COPOLYMER BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS | BASF SE (DE) | 2008-03-20 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5101070-A | From an acetoacetic acid ester; by-product minimization | NIPPON GOHSEI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-03-31 | — | — | US | disclosed |
| US-5101070-A | From an acetoacetic acid ester; by-product minimization | NIPPON GOHSEI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458049-B2 | Steviol glycoside solubility enhancers | SI, TAS2R7, TAS2R31 | GABRP 1030/4885GABRD 1785/4885GABRA1 1735/4885 |
| US-20260013535-A1 | STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS | TAS2R7, TAS2R31, TAS2R40 | GABRP 940/4885GABRD 1178/4885GABRA1 2198/4885 |
| US-20220323528-A1 | STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS | SI, TAS2R7, TAS2R31 | GABRP 1030/4885GABRD 1785/4885GABRA1 1735/4885 |
| US-11717549-B2 | Steviol glycoside solubility enhancers | SI, TAS2R7, TAS2R31 | GABRP 1030/4885GABRD 1785/4885GABRA1 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.